In the assessment of 12-month price targets, analysts unveil insights for Illumina, presenting an average target of $105.18, a high estimate of $185.00, and a low estimate of $77.00. Observing a ...

NEW YORK, July 7, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global mRNA ...

In recent years, Novogene Europe has systematically integrated state-of-the-art technologies across its service portfolio, ...

The rapid identification of respiratory virus outbreaks is needed to enable rational and effective public health interventions. We developed new quantitative approaches for simultaneous ...

Illumina, Inc. (NASDAQ:ILMN) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Illumina, Inc.

MicroGenDX Ushers in Next-Day NGS Results ORLANDO, FLORIDA / ACCESS Newswire / July 7, 2025 / MicroGenDX, a national leader ...

Illumina is estimated to have around 80% of the global DNA sequencing market, with Element one of a new generation of rivals alongside the likes of PacBio and Singular Genomics, which launched ...

23 analysts are following Illumina and have set target prices ranging from $70.0 to $185.0 per share. On average, they have given the company a rating of buy. At today's prices, ILMN is trading -7.75% ...

Artificial intelligence (AI) transforms oncology by enhancing decision-making, improving patient care, and streamlining ...

The advent of next-generation sequencing has made possible genome analysis at previously unattainable depth. Roche, Illumina and Life Technologies, among others, have developed well-established ...